# Pre-operative Chemo (CPT11, Cisplatin), Radiotherapy, Plus Surgery for Resectable Esophageal Cancer

> **NCT00160875** · PHASE2,PHASE3 · COMPLETED · sponsor: **University Health Network, Toronto** · enrollment: 54 (actual)

## Conditions studied

- Esophageal Cancer

## Interventions

- **DRUG:** Irinotecan hydrochloride trihydrate
- **DRUG:** Cisplatin

## Key facts

- **NCT ID:** NCT00160875
- **Lead sponsor:** University Health Network, Toronto
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-04
- **Primary completion:** 2011-03
- **Final completion:** 2011-03
- **Target enrollment:** 54 (ACTUAL)
- **Last updated:** 2017-05-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00160875

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00160875, "Pre-operative Chemo (CPT11, Cisplatin), Radiotherapy, Plus Surgery for Resectable Esophageal Cancer". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00160875. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*